Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nations’ largest measles outbreak in 25 years.
Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.